Peter A Kiener - Net Worth and Insider Trading

Peter A Kiener Net Worth

The estimated net worth of Peter A Kiener is at least $36,901 dollars as of 2024-04-28. Peter A Kiener is the Chief Science Officer of Sucampo Pharmaceuticals Inc and owns about 2,023 shares of Sucampo Pharmaceuticals Inc (SCMP) stock worth over $36,414. Peter A Kiener is also the Director of Cue Biopharma Inc and owns about 357 shares of Cue Biopharma Inc (CUE) stock worth over $487. Details can be seen in Peter A Kiener's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Peter A Kiener has not made any transactions after 2023-03-23 and currently still holds the listed stock(s).

Transaction Summary of Peter A Kiener

Peter A Kiener Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Peter A Kiener owns 3 companies in total, including Pieris Pharmaceuticals Inc (PIRS) , Cue Biopharma Inc (CUE) , and Sucampo Pharmaceuticals Inc (SCMP) .

Click here to see the complete history of Peter A Kiener’s form 4 insider trades.

Insider Ownership Summary of Peter A Kiener

Ticker	Comapny	Transaction Date	Type of Owner
PIRS	Pieris Pharmaceuticals Inc	2023-06-21	director
CUE	Cue Biopharma Inc	2023-03-23	director
SCMP	Sucampo Pharmaceuticals Inc	2018-02-13	Chief Science Officer

Peter A Kiener Latest Holdings Summary

Peter A Kiener currently owns a total of 2 stocks. Among these stocks, Peter A Kiener owns 2,023 shares of Sucampo Pharmaceuticals Inc (SCMP) as of December 7, 2017, with a value of $36,414 and a weighting of 98.68%. Peter A Kiener also owns 357 shares of Cue Biopharma Inc (CUE) as of March 23, 2023, with a value of $487 and a weighting of 1.32%.

Latest Holdings of Peter A Kiener

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
SCMP	Sucampo Pharmaceuticals Inc	2017-12-07	2,023	18.00	36,414
CUE	Cue Biopharma Inc	2023-03-23	357	1.37	487

Holding Weightings of Peter A Kiener

Peter A Kiener Form 4 Trading Tracker

According to the SEC Form 4 filings, Peter A Kiener has made a total of 0 transactions in Sucampo Pharmaceuticals Inc (SCMP) over the past 5 years. The most-recent trade in Sucampo Pharmaceuticals Inc is the sale of 50,000 shares on December 7, 2017, which brought Peter A Kiener around $825,000.

According to the SEC Form 4 filings, Peter A Kiener has made a total of 2 transactions in Cue Biopharma Inc (CUE) over the past 5 years, including 0 buys and 2 sells. The most-recent trade in Cue Biopharma Inc is the sale of 9,325 shares on March 23, 2023, which brought Peter A Kiener around $30,586.

Insider Trading History of Peter A Kiener

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Peter A Kiener Trading Performance

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Peter A Kiener Ownership Network

Ownership Network List of Peter A Kiener

No Data

Ownership Network Relation of Peter A Kiener

Peter A Kiener Owned Company Details

What does Pieris Pharmaceuticals Inc do?

Who are the key executives at Pieris Pharmaceuticals Inc?

Peter A Kiener is the director of Pieris Pharmaceuticals Inc. Other key executives at Pieris Pharmaceuticals Inc include 10 percent owner Bvf Gp Holdings Llc , other: See Explanation of Responses Bvf Ii Gp Llc , and 10 percent owner Bvf I Gp Llc .

Pieris Pharmaceuticals Inc (PIRS) Insider Trades Summary

Over the past 18 months, Peter A Kiener made no insider transaction in Pieris Pharmaceuticals Inc (PIRS). Other recent insider transactions involving Pieris Pharmaceuticals Inc (PIRS) include a net purchase of 10,000 shares made by Christopher P Kiritsy ,

In summary, during the past 3 months, insiders sold 0 shares of Pieris Pharmaceuticals Inc (PIRS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Pieris Pharmaceuticals Inc (PIRS) were sold and 125 shares were bought by its insiders, resulting in a net purchase of 125 shares.

Pieris Pharmaceuticals Inc (PIRS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pieris Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cue Biopharma Inc do?

Who are the key executives at Cue Biopharma Inc?

Peter A Kiener is the director of Cue Biopharma Inc. Other key executives at Cue Biopharma Inc include President and CSO Anish Suri , director & CEO Daniel R Passeri , and Chief Medical Officer Matteo Levisetti .

Cue Biopharma Inc (CUE) Insider Trades Summary

Over the past 18 months, Peter A Kiener made 1 insider transaction in Cue Biopharma Inc (CUE) with a net sale of 9,325. Other recent insider transactions involving Cue Biopharma Inc (CUE) include a net purchase of 4,000 shares made by Anish Suri , a net purchase of 3,000 shares made by Daniel R Passeri ,

In summary, during the past 3 months, insiders sold 0 shares of Cue Biopharma Inc (CUE) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 9,325 shares of Cue Biopharma Inc (CUE) were sold and 7,000 shares were bought by its insiders, resulting in a net sale of 2,325 shares.

Cue Biopharma Inc (CUE)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cue Biopharma Inc Insider Transactions

No Available Data

What does Sucampo Pharmaceuticals Inc do?

Who are the key executives at Sucampo Pharmaceuticals Inc?

Peter A Kiener is the Chief Science Officer of Sucampo Pharmaceuticals Inc. Other key executives at Sucampo Pharmaceuticals Inc include Chief Executive Officer Peter Greenleaf , CFO Peter P. Pfreundschuh , and Sr. Vice Pres. & BD & Licensing Jones W. Bryan .

Sucampo Pharmaceuticals Inc (SCMP) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Sucampo Pharmaceuticals Inc (SCMP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Sucampo Pharmaceuticals Inc (SCMP) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Sucampo Pharmaceuticals Inc (SCMP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Sucampo Pharmaceuticals Inc Insider Transactions

No Available Data

Peter A Kiener Mailing Address

Above is the net worth, insider trading, and ownership report for Peter A Kiener. You might contact Peter A Kiener via mailing address: 40 Guest Street, Boston Ma 02135.

Discussions on Peter A Kiener

No discussions yet.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.